September 30, 2021 September 30, 2021Categories Active Clinical TrialsTrial Spotlight: Selina Luger on the PrE0905 Study for FLT3 Mutated Acute Myeloid LeukemiaThis phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
June 10, 2020 June 10, 2020Categories Active Clinical TrialsNow Enrolling: PrE0905 for Acute Myeloid LeukemiaThis phase II study is exploring the potent FLT3 inhibitor gilteritinib